Susquehanna International Group’s Cidara Therapeutics CDTX Stock Holding History

Susquehanna International Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-357,900	Closed	-$79.1M	–	13239
2025 Q4	$79.1M	Sell	357,900 -47,500	-12%	-$7.68M	0.01%	1033
2025 Q3	$38.8M	Buy	405,400 +39,200	+11%	+$2.5M	﹤0.01%	1543
2025 Q2	$17.8M	Buy	+366,200	New	+$8.8M	﹤0.01%	2124
2021 Q3	–	Sell	-1,040	Closed	-$42K	–	12776
2021 Q2	$42K	Buy	+1,040	New	+$44K	﹤0.01%	12334
2020 Q4	–	Sell	-795	Closed	-$45K	–	11046
2020 Q3	$45K	Buy	+795	New	+$56.1K	﹤0.01%	10226

Susquehanna International Group's CDTX Position: Q1 2026 in Review

Susquehanna International Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 2,388 shares — an estimated $527K sold.

Susquehanna International Group first reported a position in CDTX in Q2 2016 and held it in 15 quarters. The position peaked at $12.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Susquehanna International Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Susquehanna International Group sold 2,388 Cidara Therapeutics shares in Q1 2026, an estimated $527K.
Susquehanna International Group first reported a position in Cidara Therapeutics in Q2 2016 and held it in 15 quarters.
Susquehanna International Group's Cidara Therapeutics position peaked at $12.8M in Q3 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.